<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05032339</url>
  </required_header>
  <id_info>
    <org_study_id>CAS-OFLYRICPP-IVDR</org_study_id>
    <nct_id>NCT05032339</nct_id>
  </id_info>
  <brief_title>Evaluation of the Plasma Cell Disorders Panel (BD OneFlow™ PCST and BD OneFlow™ PCD) on the BD FACSLyric™ Flow Cytometer Using Leftover, De-identified Specimens</brief_title>
  <official_title>Evaluation of the Plasma Cell Disorders Panel (BD OneFlow™ PCST and BD OneFlow™ PCD) on the BD FACSLyric™ Flow Cytometer Using Leftover, De-identified Specimens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Becton, Dickinson and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Becton, Dickinson and Company</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi-site, prospective performance study to determine equivalency between the&#xD;
      investigational OneFlow PCD panel on the FACSLyric system versus the final clinical&#xD;
      diagnosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hematology laboratories rely on flow cytometry technology (in addition to classic&#xD;
      hematological methods) to aid in screening, diagnosing, and monitoring patients with&#xD;
      hematological disorders. High speed and broad applicability of flow cytometry allows for the&#xD;
      diagnosis and accurate focus on targets. Currently, there are no general consensus panels&#xD;
      being used; as a consequence, the leukemia &amp; lymphoma (L&amp;L) testing remains a single-vial&#xD;
      antibody being used, with various in-house laboratory developed tests (LDTs) being used to&#xD;
      test patient specimens. Furthermore, the analysis of flow cytometer generated data is not&#xD;
      standardized and requires a high level of expertise/training for interpretation of complex&#xD;
      data. Therefore, optimized and standardized immunostaining protocols for the diagnosis,&#xD;
      classification, and prognostic sub-classification of hematological malignancies are needed.&#xD;
&#xD;
      This Investigational panel for plasma cell disorders is intended for in vitro diagnostic use&#xD;
      for qualitative flow-cytometric immunophenotyping of plasma cell populations on the BD&#xD;
      FACSLyric flow cytometer. These reagents are used as an aid in the differential diagnosis of&#xD;
      hematologically abnormal patients having, or suspected of having, plasma cell disorders.&#xD;
&#xD;
      Enrollment will occur at up to 8 investigational sites . Data will be acquired from Eligible&#xD;
      remnant/leftover specimens on the BD FACSLyric flow cytometer and evaluated by site personnel&#xD;
      and expert analysts .&#xD;
&#xD;
      The final diagnosis and the affected cell population will be determined by site standard of&#xD;
      care .&#xD;
&#xD;
      Analysis of data will evaluate identification of normal vs abnormal cell population of the&#xD;
      expert &amp; site analysts as compared to the final diagnosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 4, 2021</start_date>
  <completion_date type="Anticipated">March 14, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 14, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison between expert analysts' determination of normal and abnormal specimen and final diagnosis</measure>
    <time_frame>Age of specimen for Peripheral Blood (PB) andBone Marrow (BM) (time of collection to start of first pre-wash): ≤ 24 hours.</time_frame>
    <description>Determine equivalence between the investigational OneFlow PCD Panel on FACSLyric system results analyzed by two independent experts versus the final clinical diagnosis for normal polyclonal plasma cells or abnormal plasma cells using leftover, hematologically abnormal specimens.&#xD;
Sensitivity and specificity will be calculated .</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Plasma Cell Disorder</condition>
  <arm_group>
    <arm_group_label>Remnant/ Leftover specimens</arm_group_label>
    <description>Specimens that meet inclusion/exclusions criteria and are leftover from routine flow cytometry testing for plasma cell disorders</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>IUO Plasma Cell Disorders Panel</intervention_name>
    <description>This Investigational Panel , comprised of 2 reagents , is intended for in vitro diagnostic use for qualitative flow-cytometric immunophenotyping of plasma cell populations. These reagents are used as an aid in the differential diagnosis of hematologically abnormal patients having, or suspected of having, plasma cell disorders.</description>
    <arm_group_label>Remnant/ Leftover specimens</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        A minimum of 150 remnant/leftover bone marrow specimens from routine flow cytometry&#xD;
        laboratory testing for plasma cell disorders, other hematological disorders,&#xD;
        non-hematological tumors, and other hematological disorders (non-malignant). Specimens from&#xD;
        healthy subjects will be excluded.&#xD;
&#xD;
        At least 75 specimens must have abnormal plasma cells, at least 75 must have normal&#xD;
        polyclonal plasma cells.&#xD;
&#xD;
        Specimens are from subjects irrespective of race, gender, and ethnicity. Subjects above 22&#xD;
        years of age&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Specimen collected/handled prior to enrollment in accordance with site policies and&#xD;
             procedures.&#xD;
&#xD;
          2. Specimen with adequate volume (approximately 300 µL) to complete protocol tests.&#xD;
&#xD;
          3. Specimen is leftover BM from routine flow cytometry laboratory testing for plasma cell&#xD;
             disorders, other hematological disorders, non-hematological tumors, and other&#xD;
             hematological disorders (non-malignant).&#xD;
&#xD;
          4. Specimen from a newly diagnosed or relapsed subject.&#xD;
&#xD;
          5. Specimen is stored at room temperature, upon receipt by the site.&#xD;
&#xD;
          6. Age of specimen (time of collection to start of first pre-wash): ≤24 hours.&#xD;
&#xD;
          7. Specimen collected in EDTA (K2 or K3) or heparin (sodium or lithium).&#xD;
&#xD;
          8. Specimens are from subjects irrespective of race, gender, and ethnicity.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Specimen from healthy subject.&#xD;
&#xD;
          2. Specimen from subject &lt;22 years old.&#xD;
&#xD;
          3. Specimen from subject undergoing any treatment for any form of L&amp;L.&#xD;
&#xD;
          4. Specimen from subject with minimal residual disease (MRD) as determined by site.&#xD;
&#xD;
          5. Visibly clotted specimen.&#xD;
&#xD;
          6. Visibly hemolyzed specimen.&#xD;
&#xD;
          7. Frozen specimen.&#xD;
&#xD;
          8. Refrigerated specimen.&#xD;
&#xD;
          9. Fixed specimen.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Imelda Omana-Zapata, MD, PHD</last_name>
    <role>Study Director</role>
    <affiliation>Becton, Dickinson and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kimberly Dean</last_name>
    <phone>669-254-0972</phone>
    <email>kimberly_dean@bd.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Imelda Omana-Zapata, MD, PHD</last_name>
    <email>imelda_omana-zapata@bd.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Schmitz</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Corepath Laboratories</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aamir Ehsaan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fleury Group</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alex Freire Sandes</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Champalimaud Foundation</name>
      <address>
        <city>Lisbon</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carla Marisa Costa Nunes</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Alberto Orfao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Aarau</name>
      <address>
        <city>Aarau</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Fernandez</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cambridge university hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Bloxham</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 27, 2021</study_first_submitted>
  <study_first_submitted_qc>August 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2021</study_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>leukemia &amp; lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paraproteinemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

